# Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success

> **NIH NIH UL1** · ROCKEFELLER UNIVERSITY · 2022 · $3,681,571

## Abstract

The overall vision of the Rockefeller University Center for Clinical and Translational 
Science (CCTS), supported by the CTSA program, is to develop, demonstrate, and disseminate 
innovative programs so as to create a model clinical research enterprise built on rigor, 
responsible and transparent reporting, and scientific integrity to empower translation of 
paradigm-breaking discoveries into better human health. Our new initiatives are designed to: 1) 
ensure that all of our studies set the highest standards; 2) ensure that our trainees have the team 
 science leadership skills needed for a career in translational science; and 3) enhance 
 scientific rigor, reproducibility, and reporting. These new areas build on the 
infrastructure we have developed to integrate mechanistic science into community engagement, 
reach out to basic scientists, speed the development of health- enhancing products, and create an 
optimal training environment. Our specific aims are: 1. To provide a robust infrastructure to 
support the conduct of clinical investigation at the highest levels of participant safety, 
scientific rigor, bioethics, and regulatory compliance. We will enhance our multidisciplinary 
Translational Research Navigation (TRN) Program and our collaboration with Clinical Directors 
Network (CDN), a Practice Based Research Network of Community Health Centers, to ensure that our 
studies meet the highest standards of design, feasibility, method validity, and transparent 
reporting, supporting our active participation in the CTSA Trial Innovation Network. 2. To ensure 
that every discovery at Rockefeller has the best chance of improving human health. We will enhance 
our robust pipeline of programs to support basic and clinical investigators move their 
paradigm-breaking discoveries into new therapeutics by leveraging the resources of the 
Tri-Institutional Therapeutic Development Institute, the Robertson Therapeutic Development Fund, 
and the University affiliated biotechnology company, Bridge Medicines .3. To educate the entire 
research workforce team in conducting translational research at the highest levels of participant 
safety, scientific rigor, bioethics, and regulatory compliance. We will further enhance the 
multidisciplinary team science emphasis of our educational programs for KL2 Clinical Scholars, 
Clinical Research Nurses, basic scientists, and community clinicians, with a focus on our new 
Team Science Leadership training with the CTSA Hubs at Yale, University of 
Pennsylvania, and Columbia. 4. To study and improve the clinical research enterprise both at 
Rockefeller and nationally. We will continue to use the CCTS as a laboratory for investigating the 
clinical research enterprise itself and methods to improve it, including obtaining outcome data 
from research participants, enhancing rigor, reproducibility and reporting, speeding the evaluation 
of novel therapeutics via in-house formulation, and creating 'super teams' of CTSA Hubs t...

## Key facts

- **NIH application ID:** 10413256
- **Project number:** 5UL1TR001866-07
- **Recipient organization:** ROCKEFELLER UNIVERSITY
- **Principal Investigator:** Barry Coller
- **Activity code:** UL1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $3,681,571
- **Award type:** 5
- **Project period:** 2016-07-05 → 2026-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10413256

## Citation

> US National Institutes of Health, RePORTER application 10413256, Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success (5UL1TR001866-07). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10413256. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*